@article{996e5fb9aff642b998d14276a2e500f8,
title = "Clinical Pharmacogenetics Implementation Consortium Guideline for HLA Genotype and Use of Carbamazepine and Oxcarbazepine: 2017 Update",
abstract = "The variant allele HLA-B*15:02 is strongly associated with greater risk of Stevens–Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) in patients treated with carbamazepine or oxcarbazepine. The variant allele HLA-A*31:01 is associated with greater risk of maculopapular exanthema, drug reaction with eosinophilia and systemic symptoms, and SJS/TEN in patients treated with carbamazepine. We summarize evidence from the published literature supporting these associations and provide recommendations for carbamazepine and oxcarbazepine use based on HLA genotypes.",
author = "Phillips, {Elizabeth J.} and Chonlaphat Sukasem and Michelle Whirl-Carrillo and M{\"u}ller, {Daniel J.} and Dunnenberger, {Henry M.} and Wasun Chantratita and Barry Goldspiel and Chen, {Yuan Tsong} and Carleton, {Bruce C.} and George, {Alfred L.} and Taisei Mushiroda and Teri Klein and Gammal, {Roseann S.} and Munir Pirmohamed",
note = "Funding Information: This work was funded by the National Institutes of Health (NIH) for CPIC (R24GM115264) and PharmGKB (R24GM61374). E.J.P. receives funding from the NIH: 1P50GM115305-01, 1R01AI103348-01, 1P30AI110527-01A1, 5T32AI007474-20, 1R13AR71267-01, National Health & Medical Research Council of Australia, and Australian Centre for HIV and Hepatitis Virology Research. B.C.C. receives funding from the Pharmaceutical Outcomes Programme (POPi), which has received financial support for its pharmacogenetics research from the following government-funded agencies in Canada: Canada Foundation for Innovation (CFI), Canadian Institutes of Health Research (CIHR), Genome Canada, Genome British Columbia and the Provincial Health Services Authority, the University of British Columbia, and British Columbia Children's Hospital Research Institute. M.P. receives funding from the NIHR (NIHR Senior Investigator), MRC (MRC Centre for Drug Safety Science), the international Serious Adverse Event Consortium (iSAEC), NIHR CLAHRC North-West Coast and the Wolfson Foundation. We acknowledge the critical input of Dr. M. Relling and members of the Clinical Pharmacogenetics Implementation Consortium (CPIC) of the Pharmacogenomics Research Network, funded by the National Institutes of Health. CPIC members are listed here: https://cpicpgx.org/members/. Funding Information: This work was funded by the National Institutes of Health (NIH) for CPIC (R24GM115264) and PharmGKB (R24GM61374). E.J.P. receives funding from the NIH: 1P50GM115305-01, 1R01AI103348-01, 1P30AI110527-01A1, 5T32AI007474-20, 1R13AR71267-01, National Health & Medical Research Council of Australia, and Australian Centre for HIV and Hepatitis Virology Research. B.C.C. receives funding from the Pharmaceutical Outcomes Programme (POPi), which has received financial support for its pharmacogenetics research from the following government-funded agencies in Canada: Canada Foundation for Innovation (CFI), Canadian Institutes of Health Research (CIHR), Genome Canada, Genome British Columbia and the Provincial Health Services Authority, the University of British Columbia, and British Columbia Children{\textquoteright}s Hospital Research Institute. M.P. receives funding from the NIHR (NIHR Senior Investigator), MRC (MRC Centre for Drug Safety Science), the international Serious Adverse Event Consortium (iSAEC), NIHR CLAHRC North-West Coast and the Wolfson Foundation. Publisher Copyright: {\textcopyright} 2018 American Society for Clinical Pharmacology and Therapeutics",
year = "2018",
month = apr,
doi = "10.1002/cpt.1004",
language = "English (US)",
volume = "103",
pages = "574--581",
journal = "Clinical pharmacology and therapeutics",
issn = "0009-9236",
publisher = "Nature Publishing Group",
number = "4",
}